CDiddy, I didn't say anything about money or selling 2
CDiddy, I didn't say anything about money or selling 2 billion doses of Leronlimab. The only price I talked about was hoping the eventual price of Leronlimab would be that of some Southern Comfort.
The price of the vaccines so far as I know is Zero to the people getting them now.
I'm sorry you took offense to my use of the argument technique of "reductio ad absurdum" to illustrate the objective need for Leronlimab. But the argument has already been made by BP with the number of vaccine doses they are pledging to manufacture.
I don't think I was engaged in unrealistic pumping. But I am glad to be on record with my opinion. It may not all be Leronlimab but we are the ones on the right track.
4
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
U.S. Battery Supply Set for a Boost Ah, the thrill of a conditional commitment—it's not quite a done deal, but it's a step in the right direction. 6K Inc., with its roots in Massachusetts, is on the brink of transforming the American battery supply chain after announcing a whopping $250 million loan commitment from none other than the U.S. Department of War. This move...
Continue Reading
AlphaESS: Consistency Breeds Success Can't ignore a company that keeps hitting the marks quarter after quarter, kid. AlphaESS just bagged its fifth consecutive Tier 1 status from BloombergNEF for Q4 2026—that's no joke in the buzzing world of energy storage. What makes this outfit tick? It's not just sticking to the same old script; they keep leveling up while everyone...
Continue Reading
Hospital Hiring Gets a Tech Boost In the bustling world of healthcare recruitment, it's like trudging through quicksand with a time bomb strapped to your back. That's where PSG Global Solutions sauntered into the Las Vegas spotlight with Anna AI, their generative AI marvel that just snagged the Innovative Technology designation from Vizient. This ain’t your...
Continue Reading
Sausage Politics: A Tasty New Agenda Well, ain't that something? A sausage campaign running parallel to the midterms wasn't exactly on my bingo card. But here we are, America, dealing with a 'Sausage Tsunami.' This cheeky strategy from Johnsonville sure packs a punch, leveraging electoral fatigue to put sausage right where they want it: on your dinner plate. The Campaign...
Continue Reading
Manulife's Resilience in a Volatile Market Trading has a way of keeping folks on their toes. Just when you think you've ridden the bull long enough, it tries bucking you off. That's how it goes for Manulife Financial Corporation (TSX/NYSE/PSE: MFC), as they reported their Q3 2026 results—marking a seesaw of gains and losses. Core Earnings Shine While Net Income Declines...
Continue Reading
Anticipation Builds for ATRenew's Q3 Release Alright folks, mark your calendars and get that caffeine ready—November 19th is about to be interesting for those tracking NYSE: RERE. ATRenew, the tech-driven recycling pioneer, will drop its latest financial crumbs before the U.S. market wakes up. Another earnings call to dissect, and hopefully, one that doesn't bore us to...
Continue Reading
A New Dawn for Enterprise Modernization Modernizing enterprise infrastructure today ain't just about wading through outdated code lines. Kyndryl (NYSE: KD) is flipping the script, with their latest partnership with Amazon Web Services (AWS) aiming to make modernization swift, continuous, and AI-ready. Gone are the days of treating technology upgrades as a one-off event....
Continue Reading
America’s democracy is getting its moment in the spotlight over at Long Island University, and it's more than just statues and old papers. This exhibition, "The Presidency & Promise of America: A More Perfect Union," unpacked on October 28, throws open a window into the U.S.'s democratic journey from its scrappy beginnings to today’s hot zones of political debate. And...
Continue Reading
Fosun's Nine-Year CIIE Journey Fosun's been trotting out its innovations at the China International Import Expo (CIIE) for nine straight years. With 162 countries in the mix this time around, they're not just playing house—it’s downright world-class boasting. Fosun’s rolling out their hard-hitters in the medical tech space, showing they’re no rookies to the...
Continue Reading
The Hidden Pitfalls of DIY Inflatable Rentals You wouldn't expect renting an inflatable for a backyard bash in Dallas to be such a tangled mess, but that’s exactly where families find themselves time and again. Planning a celebration without an expert can quickly spiral into a safety nightmare. We often assume that plunking an inflatable down and watching the fun unfold...
Continue Reading
Top 5 Most Recently Viewed Articles
Join the Upcoming Class Action Against Walgreens for WBA Shareholders The Gross Law Firm has issued an important notice for shareholders of Walgreens Boots Alliance, Inc. (NASDAQ: WBA) regarding a potential class action lawsuit. If you purchased shares of WBA within the specified dates, you may want to consider your options for participation. Class Action Overview This...
Continue Reading
US Employment Surge Sparks Optimism in Asian Markets By Jamie McGeever As Asian markets prepare to open, the global economic landscape is shifting dramatically, spurred by astonishing U.S. employment figures. This unexpected data has shifted market perceptions and prompted investors to reconsider their strategies. Strong September Non-Farm Payrolls Report The report on...
Continue Reading
Understanding Your Rights as a Block, Inc. Investor For investors of Block, Inc. looking to recover their losses, it's crucial to understand the legal avenues available to them. The recent issues surrounding Block should encourage affected investors to seek assistance promptly. How to Recover Losses The Portnoy Law Firm is available to help investors navigate the...
Continue Reading
Highlights from Implantica AG's Annual General Meeting On a recent date, the annual general meeting (AGM) of Implantica AG (publ) took place in Ruggell. This important gathering allowed shareholders to review key proposals and resolutions put forth by the board of directors, all of which were adopted. Below is a detailed overview of the notable decisions made during this...
Continue Reading
Key Findings from BRIUMVI's 5-Year Trials TG Therapeutics, Inc. (NASDAQ:TGTX) has revealed impressive results from its long-term Phase 3 trials, ULTIMATE I & II, which focus on BRIUMVI (ublituximab-xiiy) for treating relapsing forms of multiple sclerosis (RMS). These findings were presented at the respected European Committee for Treatment and Research in Multiple...
Continue Reading